Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ANIX
- Price
- 2.58
- Stock movement down
- -0.08 (-3.01%)
- Company name
- Anixa Biosciences Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 83.02M
- Ent value
- 84.02M
- Price/Sales
- 532.20
- Price/Book
- 4.01
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -16.79%
- 1 year return
- -19.38%
- 3 year return
- -0.64%
- 5 year return
- 8.96%
- 10 year return
- 3.96%
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ANIX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 532.20 |
| Price to Book | 4.01 |
| EV to Sales | 538.56 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 32.18M |
| EPS (TTM) | -0.39 |
| FCF per share (TTM) | -0.26 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 156.00K |
| Gross profit (TTM) | 116.00K |
| Operating income (TTM) | -13.72M |
| Net income (TTM) | -12.36M |
| EPS (TTM) | -0.39 |
| EPS (1y forward) | -0.46 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 74.36% |
| Operating margin (TTM) | -8794.23% |
| Profit margin (TTM) | -7923.72% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.23M |
| Net receivables | 410.00K |
| Total current assets | 22.67M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 238.00K |
| Total assets | 22.91M |
| Accounts payable | 302.00K |
| Short/Current long term debt | 237.00K |
| Total current liabilities | 2.00M |
| Total liabilities | 2.22M |
| Shareholder's equity | 20.69M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -8.38M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -8.38M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -59.74% |
| Return on Assets | -53.96% |
| Return on Invested Capital | -59.60% |
| Cash Return on Invested Capital | -40.39% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.70 |
| Daily high | 2.74 |
| Daily low | 2.55 |
| Daily Volume | 63K |
| All-time high | 242.19 |
| 1y analyst estimate | 8.50 |
| Beta | 0.85 |
| EPS (TTM) | -0.39 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ANIX | S&P500 | |
| Current price drop from All-time high | -98.93% | -12.89% |
| Highest price drop | -99.75% | -56.47% |
| Date of highest drop | 15 Aug 2017 | 9 Mar 2009 |
| Avg drop from high | -81.64% | -11.07% |
| Avg time to new high | 353 days | 12 days |
| Max time to new high | 7203 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
83.02M
Marketcap category
Small-cap
Description
Anixa Biosciences, Inc., a clinical-stage biotechnology company, focuses on the treatment and prevention of cancer. Its therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer " primarily triple negative breast cancer (TNBC), the lethal form of the disease, as well as a vaccine to prevent ovarian cancer. Its vaccine technologies focus on immunizing against retired proteins that found to be expressed in certain forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Employees
4
Website
Investor relations
-
SEC filings
CEO
Amit Kumar
Country
USA
City
San Jose
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page